abrocitinib (Cibinqo) Report issue

Small molecule Approved FDA Breakthrough Therapy FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
  • InChIKey: IUEWXNHSKRWHDY-PHIMTYICSA-N
  • Mol. Mass: 323.42
  • ALogP: 1.25
  • ChEMBL Molecule:
    abrocitinib  
More Chemistry

Pharmacology

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Dermatitis, Atopic (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Dermatitis, Atopic (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Food Hypersensitivity (Phase 1)

Granuloma Annulare (Phase 2)

Healthy Volunteers (Phase 1)

Prurigo (Phase 2)

Pruritus (Phase 2)

Sarcoidosis (Phase 2)

Skin Diseases (Phase 2)

Stevens-Johnson Syndrome (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue